TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03219827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: Blood samples collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: Blood samples collection
Study: NCT03792022

Intervention type: BEHAVIORAL
Intervention: Adherence to timely vaccine uptake
Description: Adherence to timely vaccine uptake
Study: NCT01737073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR self-management
Description: A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR self-management
Description: A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid monitoring
Description: Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid monitoring
Description: Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced usual care
Description: Weekly automated wellness tip and usual clinical care
Study: NCT02827734

Intervention type: DEVICE
Intervention: multiple breath washout tests

Intervention type: DEVICE
Intervention: multiple breath washout tests

Intervention type: DEVICE
Intervention: impulse oscillometry

Intervention type: DEVICE
Intervention: impulse oscillometry

Intervention type: DEVICE
Intervention: body plethysmography

Intervention type: DEVICE
Intervention: body plethysmography
Study: NCT02521649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G17DT
Study: NCT01391715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole
Description: rabeprazole 20mg bid per day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard dose rabeprazole
Description: rabeprazole 20mg qd per day for 2 weeks
Study: NCT02950428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE neo™TA Delivery System
Description: ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
Study: NCT01652014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV daily over 30 minutes for 5 days (Days -6 to -2)
Study: NCT00512785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imidafenacin, KRP-197/ONO-8025
Description: 0.1 mg BID for 52 weeks
Study: NCT02463097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump
Description: Closed Loop Algorithm
Study: NCT01652014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV daily over 30 minutes for 5 days (Days -6 to -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO 1.0 g BID Day 1-30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO 1.0 g BID Day 1-30

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo double-unit allogeneic UCB transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Undergo single allogeneic UCB transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double-unit umbilical cord blood transplantation
Description: Undergo double-unit allogeneic UCB transplant
Study: NCT04175288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound, manual therapy and exercise
Description: The experimental group will receive ultrasound (US) for 3 sessions a week for 4 weeks, with continuous US (1.8 w/cm2, 1 Mega Hz 8 minutes). Manual therapy will include posterior glides to talocrural joint, subtalar lateral glide, a 1st tarsometatarsal joint dorsal glide and extension mobilization to the 1st metatarsophalangeal joint. All participants in each group will be given specific exercises by the investgators targeting intrinsic and extrinsic muscles of the foot and ankle. Specific stretches for the plantar fascia and Achilles tendon, will be performed. Home exercises will be recorded using a log.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound, manual therapy and exercise
Description: The experimental group will receive ultrasound (US) for 3 sessions a week for 4 weeks, with continuous US (1.8 w/cm2, 1 Mega Hz 8 minutes). Manual therapy will include posterior glides to talocrural joint, subtalar lateral glide, a 1st tarsometatarsal joint dorsal glide and extension mobilization to the 1st metatarsophalangeal joint. All participants in each group will be given specific exercises by the investgators targeting intrinsic and extrinsic muscles of the foot and ankle. Specific stretches for the plantar fascia and Achilles tendon, will be performed. Home exercises will be recorded using a log.
Study: NCT01848600

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: interpretation of the abstract
Description: the intervention consist to interpret the results of the meta-analysis after reading the abstract.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpretation of the abstract
Description: the intervention consist to interpret the results of the meta-analysis after reading the abstract.
Study: NCT03400592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV once every 2 weeks until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: 400mg IV once weekly until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
Study: NCT02729571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Live-attenuated tuberculosis vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Live-attenuated tuberculosis vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Live-attenuated tuberculosis vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Commercially available live-attenuated tuberculosis vaccine
Study: NCT01595685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: Telbivudine 600 mg Daily Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5 mg Daily Oral
Study: NCT01652014

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study: NCT03935698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study: NCT03392350

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Body Scan Consultation with Behavioral Intervention
Description: The RENEW™ program consisted of 7 bi-monthly face-to-face web sessions over 16-18 weeks followed by an average of 15 monthly check-in sessions (maintenance) over 80 weeks.This included modules on responding to stress, enhancing effects of relaxation, nourishing theimmune system, physical activity, and social support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Body Scan Consultation with Behavioral Intervention
Description: The RENEW™ program consisted of 7 bi-monthly face-to-face web sessions over 16-18 weeks followed by an average of 15 monthly check-in sessions (maintenance) over 80 weeks.This included modules on responding to stress, enhancing effects of relaxation, nourishing theimmune system, physical activity, and social support.
Study: NCT05980845

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nature sounds
Description: Nature sounds would be played for 30 minutes in three HD sessions for one week, starting from the beginning of the session. Afterwards, the patients were informed about the usage of the Mp3 player and in-ear headphones, they were demonstrated that they could adjust the volume to the level they desired, and it was stated that they should not detach the headphones until the 30-minute recording was over.
Study: NCT00246324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a, oral doxycycline
Description: Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
Study: NCT03930537

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip replacement
Description: The hip replacement surgery is when a damaged hip is replaced with artificial one

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip replacement
Description: The hip replacement surgery is when a damaged hip is replaced with artificial one
Study: NCT01922505

Intervention type: DRUG
Intervention: PPI triple therapy
Study: NCT03299582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
Study: NCT03333044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW)-Led Health Coaching
Description: CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to manage diabetes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR-Embedded Alerts
Description: An electronic health record (EHR) intervention for primary care providers (PCPs) utilizing embedded alerts to identify South Asian patients with uncontrolled diabetes.
Study: NCT03299582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryocompression
Description: Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryocompression
Description: Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
Study: NCT01245283

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal activities and clinical care
Description: Subjects will continue to participate in their normal activities and clinical care during the four month study. Telephone contact will be made weekly to encourage adherence to the knee management guidelines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concentric Focused Resistance Exercise
Description: Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
Study: NCT01652014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo single allogeneic UCB transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo irradiated allogeneic peripheral blood stem cell transplant
Study: NCT01245283

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Focused Resistance Exercise
Description: Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
Study: NCT00512785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imidafenacin, KRP-197/ONO-8025
Description: 0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
Study: NCT04414865

Intervention type: DEVICE
Intervention: VitaFlow™ Transcatheter Aortic Valve System
Description: VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
Study: NCT04330573

Intervention type: OTHER
Intervention: No intervention. Observational study
Description: Observational study

Intervention type: OTHER
Intervention: No intervention. Observational study
Description: Observational study
Study: NCT03943602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60 mg/day orally
Study: NCT01957904

Intervention type: DEVICE
Group type: OTHER
Intervention: ArterX Surgical Sealant
Study: NCT00921973

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAX102
Description: All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
Study: NCT00512265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-acetylcysteine
Description: 150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 250mL glucose 5%
Description: placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
Study: NCT01169935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of intra-dermal Endorem
Description: single dose, intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mantoux test
Description: single dose, intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mantoux test
Description: single dose, intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mantoux test
Description: single dose, intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mantoux test
Description: single dose, intradermal
Study: NCT02391766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: empowerment
Description: The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Study: NCT03635645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New visual processing unit (VPU) with asymmetric waveforms
Description: A VPU will apply asymmetric and symmetric stimulation pulses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New VPU with bipolar stimulation
Description: A VPU will apply bipolar stimulus pulses.
Study: NCT01029925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Description: Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
Study: NCT02858206

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT simultaneous integrated boost
Description: To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT simultaneous integrated boost
Description: To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT simultaneous integrated boost
Description: To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT simultaneous integrated boost
Description: To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
Study: NCT01169935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Endorem-labelled mononuclear cells
Description: single dose, intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Endorem-labelled mononuclear cells
Description: single dose, intravenous
Study: NCT02858206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Radical esophagectomy 4-6 weeks after neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Radical esophagectomy 4-6 weeks after neoadjuvant therapy
Study: NCT02951806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (R) Rapid spinal fentanyl injection
Description: Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
Study: NCT03317431

Intervention type: OTHER
Intervention: mechanical ventilation
Description: mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
Study: NCT01169935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Endorem
Description: single dose, intravenous
Study: NCT03308253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulan Rapid Cure
Description: Calcium sulfate dissolvable beads

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 0.5 g Vancomycin per patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Description: 120 mg tobramycin per patient

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
Study: NCT02229409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walkadoo
Description: Walkadoo is a MeYou Health, LLC product.
Study: NCT04415411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing care based on the Theory of Human Caring
Description: Planned nursing care based on 10 caritas processes of Theory of Human Caring.
Study: NCT04725500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Titrating EPAP
Description: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
Study: NCT03163901

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic Manipulative Treatment
Description: OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment
Description: OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
Study: NCT02023684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control saline
Description: Surgical bed irrigation with saline 40ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: surgical bed Irrigation Lidocaine 0.5%, 40ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: surgical bed Irrigation Ropivacaine 0.2%, 40ml
Study: NCT00662545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir with continued standard of care antiretroviral therapy
Description: 1 mg by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continued standard of care with tenofovir in addition to emtricitabine or lamivudine
Description: continued standard of care with tenofovir in addition to emtricitabine or lamivudine
Study: NCT00627341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)
Description: AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.